Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistant Streptococcus pneumoniae.
The in vitro and in vivo antipneumococcal activities of the main pneumococcal autolysin (LytA) and Cpl-1, a lysozyme encoded by phage Cp-1, were studied. Intraperitoneal therapy with LytA or high-dose Cpl-1 remarkably reduced peritoneal bacterial counts (>5 log(10) CFU/ml) compared with those for the controls. After intravenous injection, LytA was the most effective treatment.
Rodríguez-Cerrato
Violeta
V
Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz, Avenida de Reyes Católicos 2, 28040 Madrid, Spain.
García
Pedro
P
Huelves
Lorena
L
García
Ernesto
E
Del Prado
Gema
G
Gracia
Matilde
M
Ponte
Carmen
C
López
Rubens
R
Soriano
Francisco
F
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000382:microbiology; D001435:Bacteriophages / Q000235:genetics; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D008826:Microbial Sensitivity Tests; D009113:Muramidase / Q000627:therapeutic use; D009238:N-Acetylmuramoyl-L-alanine Amidase / Q000494:pharmacology / Q000627:therapeutic use*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D011008:Pneumococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000737:chemistry* / Q000187:drug effects*; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; C067928:CPL7 lysozyme; D009113:Muramidase; D009238:N-Acetylmuramoyl-L-alanine Amidase